Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemie, limfocitică, cronică, celule b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astrazeneca ab - acalabrutinibum - capsule - 100 mg

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - acalabrutinibum - caps. - 100mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - acalabrutinibum - compr. film. - 100mg - inhibitori de protein-kinaza

Uniunea Europeană - română - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agenți antineoplazici - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

millmount healthcare limited - irlanda - zanubrutinibum - caps. - 80mg - inhibitori de protein-kinaza